본문 바로가기
KERD
논문KCI 등재

Aspirin for Primary Prevention of Cardiovascular Disease

심민정|이소영|오지수|김상훈|김지혜
한국지질동맥경화학회 (The Korean Society of Lipidology and Atherosclerosis)|2019.09|지질·동맥경화학회지 (Journal of Lipid and Atherosclerosis)|제8권 제2호|pp. 162-172|DOI 10.12997/jla.2019.8.2.162

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Cardiovascular diseasesPrimary preventionAspirin

초록

Aspirin has been used for decades for the primary and secondary prevention of cardiovascular disease (CVD). The effect of aspirin in secondary prevention is well-known but is still debatable for primary prevention. Despite the controversy, aspirin is believed to have a beneficial effect in primary prevention and has been widely used. However, whether the doubts concerning the wide use of aspirin are correct has resulted in the publication of data from several large clinical trials recently. There are several clinical guidelines from various international organizations on the use of aspirin for the primary prevention of CVD, and they offer some conflicting recommendations. A reduction in the overall incidence of CVD with the development of modern prevention therapies has weakened the impact of aspirin in primary prevention. Large randomized clinical trials have found decreased or no difference in CVD events but a significant increase in the risk of bleeding. Taking aspirin for the primary prevention of CVD is no longer recommended, especially for patients who have a low to moderate risk. An assessment of the balance between the benefits and risks of aspirin use should be considered.

Abstract

Aspirin has been used for decades for the primary and secondary prevention of cardiovascular disease (CVD). The effect of aspirin in secondary prevention is well-known but is still debatable for primary prevention. Despite the controversy, aspirin is believed to have a beneficial effect in primary prevention and has been widely used. However, whether the doubts concerning the wide use of aspirin are correct has resulted in the publication of data from several large clinical trials recently. There are several clinical guidelines from various international organizations on the use of aspirin for the primary prevention of CVD, and they offer some conflicting recommendations. A reduction in the overall incidence of CVD with the development of modern prevention therapies has weakened the impact of aspirin in primary prevention. Large randomized clinical trials have found decreased or no difference in CVD events but a significant increase in the risk of bleeding. Taking aspirin for the primary prevention of CVD is no longer recommended, especially for patients who have a low to moderate risk. An assessment of the balance between the benefits and risks of aspirin use should be considered.

참고문헌 (50)

  1. Yusuf S, "Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization", Circulation, 104, pp.2746~2753 (2001)
  2. Yusuf S, "Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies", Circulation, 104, pp.2855~2864 (2001)
  3. Dalen JE, "The epidemic of the 20th century: coronary heart disease", Am J Med, 127, pp.807~812 (2014)
  4. Hennekens CH, "Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association", Circulation, 96, pp.2751~2753 (1997)
  5. Baigent C, "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
  6. Williams CD, "Aspirin use among adults in the U.S.: results of a national survey", Am J Prev Med, 48, pp.501~508 (2015)
  7. Mainous AG 3rd, "Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012", J Am Heart Assoc, 3, pp.e000989~ (2014)
  8. Nemerovski CW, "Aspirin for primary prevention of cardiovascular disease events", Pharmacotherapy, 32, pp.1020~1035 (2012)
  9. Wallace JL, "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself ?", Physiol Rev, 88, pp.1547~1565 (2008)
  10. Antithrombotic Trialists' Collaboration, "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", BMJ, 324, pp.71~86 (2002)
  11. Smith SC Jr, "AHA", ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association, 2011, pp.58, 2432~2446
  12. Bibbins-Domingo K, "Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement", Ann Intern Med, 164, pp.836~845 (2016)
  13. Piepoli MF, "2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)", Atherosclerosis, 252, pp.207~274 (2016)
  14. American Diabetes Association, "10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2019", Diabetes Care, 42, pp.S103~S123 (2019)
  15. Peto R, "Randomised trial of prophylactic daily aspirin in British male doctors", Br Med J (Clin Res Ed), 296, pp.313~316 (1988)
  16. Guirguis-Blake JM, "Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force", Ann Intern Med, 164, pp.804~813 (2016)
  17. Sutcliffe P, "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews", Health Technol Assess, 17, pp.1~253 (2013)
  18. American Diabetes Association, "8. Cardiovascular disease and risk management", Diabetes Care, 39(Suppl 1), pp.S60~S71 (2016)
  19. Bowman L, "Effects of aspirin for primary prevention in persons with diabetes mellitus", N Engl J Med, 379, pp.1529~1539 (2018)
  20. Gaziano JM, "Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial", Lancet, 392, pp.1036~1046 (2018)
  21. McNeil JJ, "Effect of aspirin on cardiovascular events and bleeding in the healthy elderly", N Engl J Med, 379, pp.1509~1518 (2018)
  22. Perk J, "European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)", Int J Behav Med, 19, pp.403~488 (2012)
  23. Mosca L, "Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association", J Am Coll Cardiol, 57, pp.1404~1423 (2011)
  24. De Berardis G, "Association of aspirin use with major bleeding in patients with and without diabetes", JAMA, 307, pp.2286~2294 (2012)
  25. Li L, "Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a populationbased cohort study", Lancet, 390, pp.490~499 (2017)
  26. Whitlock EP, "Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force", Ann Intern Med, 164, pp.826~835 (2016)
  27. Wilkins E, "European cardiovascular disease statistics 2017 edition" (2017), European Heart Network
  28. Benjamin EJ, "Heart disease and stroke statistics—2018 update: a report from the American Heart Association", Circulation, 137, pp.e67~e492 (2018)
  29. GBD 2015 DALYs and HALE Collaborators, "Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet, 388, pp.1603~1658 (2016)
  30. Ford ES, "Explaining the decrease in U.S. deaths from coronary disease, 1980–2000", N Engl J Med, 356, pp.2388~2398 (2007)
  31. Weir HK, "Heart disease and cancer deaths - trends and projections in the United States, 1969–2020", Prev Chronic Dis, 13, pp.E157~ (2016)
  32. García Rodríguez LA, "Bleeding risk with longterm low-dose aspirin: a systematic review of observational studies", PLoS One, 11, pp.e0160046~ (2016)
  33. Hyoung-Chul Oh, "Post-ERCP Bleeding in the Era of Multiple Antiplatelet Agents", Gut and Liver, 12(2), pp.214~218 (2018), 거트앤리버 소화기연관학회협의회
  34. So S, "Comparison of the effects of antithrombotic therapy on delayed bleeding after gastric endoscopic resection: a propensity score-matched case-control study", Gastrointest Endosc, 89, pp.277~285.e2 (2019)
  35. Van't Hof JR, "Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of US Preventive Services Task Force recommendations, 2007–2015: a serial, cross-sectional study", J Am Heart Assoc, 6, pp.e006328~ (2017)
  36. McNeil JJ, "Effect of aspirin on disability-free survival in the healthy elderly", N Engl J Med, 379, pp.1499~1508 (2018)
  37. McNeil JJ, "Effect of aspirin on all-cause mortality in the healthy elderly", N Engl J Med, 379, pp.1519~1528 (2018)
  38. Ikeda Y, "Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors:a randomized clinical trial", JAMA, 312, pp.2510~2520 (2014)
  39. Pignone M, "Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis", Ann Intern Med, 144, pp.326~336 (2006)
  40. Lanas A, "The aspirin cardiovascular", gastrointestinal risk calculator--a tool to aid clinicians in practice, 2013, pp.37, 738~748
  41. Bosch J, "Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial", Can J Cardiol, 33, pp.1027~1035 (2017)
  42. Scally B, "Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials", Lancet Gastroenterol Hepatol, 3, pp.231~241 (2018)
  43. 박용휘, "Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation", Korean Circulation Journal, 47(3), pp.366~376 (2017), 대한심장학회
  44. Kim D, "Dual versus mono antiplatelet therapy in large atherosclerotic stroke", Stroke, 50, pp.1184~1192 (2019)
  45. Kim JT, "Comparative effectiveness of aspirin and clopidogrel versus aspirin in acute minor stroke or transient ischemic attack", Stroke, 50, pp.101~109 (2019)
  46. Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
  47. 김지영, "Cardiovascular Health Metrics and All-cause and Cardiovascular Disease Mortality Among Middle-aged Men in Korea: The Seoul Male Cohort Study", 예방의학회지, 46(6), pp.319~328 (2013), 대한예방의학회
  48. Kim JH, "Multicenter Cohort Study of Acute Myocardial Infarction in Korea - Interim analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry", Circ J, 80, pp.1427~1436 (2016)
  49. Keun-Sik Hong, "Stroke Statistics in Korea: Part I. Epidemiology and Risk Factors: A Report from the Korean Stroke Society and Clinical Research Center for Stroke", 대한뇌졸중영문학회지, 15(1), pp.2~20 (2013), 대한뇌졸중학회[DOI]
  50. 심두선, "Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries", Korean Circulation Journal, 47(6), pp.811~822 (2017), 대한심장학회[DOI]

관련 논문AI추천

심뇌혈관질환 예방을 위한 아스피린의 근거중심 사용법김경곤, 김영상, 황인철대한가정의학회 · Korean Journal of Family Medicine2009 · 제30권 제4호Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery DiseaseChang Kyu Choi거트앤리버 소화기연관학회협의회 · Gut and Liver2008 · 제2권 제2호한국뇌졸중진료지침에서 아스피린의 뇌졸중 일차예방효과에 관한 내용의 부분개정강규식, 구자성, 권순억, 김한영, 나정호, 박종무, 배희준, 오창완, 유경호, 윤병우, 이병철, 조용진, 한상원, 허지회, 홍근식대한신경과학회 · 대한신경과학회지2011 · 제29권 제4호New European Society of Cardiology/European Atherosclerosis Society Guideline for the Management of Dyslipidemia정창희한국지질동맥경화학회 · 지질·동맥경화학회지2017 · 제6권 제1호Dual Antiplatelet Therapy after Noncardioembolic Ischemic Stroke or Transient Ischemic Attack: Pros and Cons홍근식대한신경과학회 · Journal of Clinical Neurology2014 · 제10권 제3호Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review김광일한국지질동맥경화학회 · 지질·동맥경화학회지2023 · 제12권 제2호

이 간행물의 다른 논문 (16건)

Mendelian Randomization Analysis in Observational Epidemiology이관, 임지연pp. 67-772018 Guidelines for the Management of Dyslipidemia in Korea한상엽, 이경희, 김혜진, 김은미, 김병진, 임정현, 이은영, 김재현, 김현창, 송윤주, 이은정, 오미선, 노정현, 문민경, 정인경, 홍순철, 나진오, 이상학, 박광열, 최성훈pp. 78-131Genetically Mediated Lipid Metabolism and Risk of Insulin Resistance: Insights from Mendelian Randomization Studies부소영pp. 132-143Diabetes-related Amylin Dyshomeostasis: a Contributing Factor to Cerebrovascular Pathology and DementiaFlorin Despa, Han Lypp. 144-151Single Cell RNA-Sequencing for the Study of AtherosclerosisMorteza Chalabi Hajkarim, 원경재pp. 152-161
원문 보기